Mechanism and properties of positive allosteric modulation of N-methyl-d-aspartate receptors by 6-alkyl 2-naphthoic acid derivatives. 2017

Kiran Sapkota, and Mark W Irvine, and Guangyu Fang, and Erica S Burnell, and Neil Bannister, and Arturas Volianskis, and Georgia R Culley, and Shashank M Dravid, and Graham L Collingridge, and David E Jane, and Daniel T Monaghan
Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198-5800, USA.

The theory that N-methyl-d-aspartate receptor (NMDAR) hypofunction is responsible for the symptoms of schizophrenia is well supported by many pharmacological and genetic studies. Accordingly, positive allosteric modulators (PAMs) that augment NMDAR signaling may be useful for treating schizophrenia. Previously we have identified several NMDAR PAMs containing a carboxylic acid attached to naphthalene, phenanthrene, or coumarin ring systems. In this study, we describe several functional and mechanistic properties of UBP684, a 2-naphthoic acid derivative, which robustly potentiates agonist responses at each of the four GluN1a/GluN2 receptors and at neuronal NMDARs. UBP684 increases the maximal l-glutamate/glycine response while having minor subunit-specific effects on agonist potency. PAM binding is independent of agonist binding, and PAM activity is independent of membrane voltage, redox state, and the GluN1 exon 5 N-terminal insert. UBP684 activity is, however, markedly pH-dependent, with greater potentiation occurring at lower pHs and inhibitory activity at pH 8.4. UBP684 increases channel open probability (Po) and slows receptor deactivation time upon removal of l-glutamate, but not glycine. The structurally related PAM, UBP753, reproduced most of these findings, but did not prolong agonist removal deactivation time. Studies using cysteine mutants to lock the GluN1 and GluN2 ligand-binding domains (LBDs) in the agonist-bound states indicate that PAM potentiation requires GluN2 LBD conformational flexibility. Together, these findings suggest that UBP684 and UBP753 stabilize the GluN2 LBD in an active conformation and thereby increase Po. Thus, UBP684 and UBP753 may serve as lead compounds for developing agents to enhance NMDAR activity in disorders associated with NMDAR hypofunction.

UI MeSH Term Description Entries
D009281 Naphthalenes Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics.
D009865 Oocytes Female germ cells derived from OOGONIA and termed OOCYTES when they enter MEIOSIS. The primary oocytes begin meiosis but are arrested at the diplotene state until OVULATION at PUBERTY to give rise to haploid secondary oocytes or ova (OVUM). Ovocytes,Oocyte,Ovocyte
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D002264 Carboxylic Acids Organic compounds containing the carboxy group (-COOH). This group of compounds includes amino acids and fatty acids. Carboxylic acids can be saturated, unsaturated, or aromatic. Carboxylic Acid,Acid, Carboxylic,Acids, Carboxylic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005998 Glycine A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. Aminoacetic Acid,Glycine, Monopotassium Salt,Glycine Carbonate (1:1), Monosodium Salt,Glycine Carbonate (2:1), Monolithium Salt,Glycine Carbonate (2:1), Monopotassium Salt,Glycine Carbonate (2:1), Monosodium Salt,Glycine Hydrochloride,Glycine Hydrochloride (2:1),Glycine Phosphate,Glycine Phosphate (1:1),Glycine Sulfate (3:1),Glycine, Calcium Salt,Glycine, Calcium Salt (2:1),Glycine, Cobalt Salt,Glycine, Copper Salt,Glycine, Monoammonium Salt,Glycine, Monosodium Salt,Glycine, Sodium Hydrogen Carbonate,Acid, Aminoacetic,Calcium Salt Glycine,Cobalt Salt Glycine,Copper Salt Glycine,Hydrochloride, Glycine,Monoammonium Salt Glycine,Monopotassium Salt Glycine,Monosodium Salt Glycine,Phosphate, Glycine,Salt Glycine, Monoammonium,Salt Glycine, Monopotassium,Salt Glycine, Monosodium
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D000494 Allosteric Regulation The modification of the reactivity of ENZYMES by the binding of effectors to sites (ALLOSTERIC SITES) on the enzymes other than the substrate BINDING SITES. Regulation, Allosteric,Allosteric Regulations,Regulations, Allosteric
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Kiran Sapkota, and Mark W Irvine, and Guangyu Fang, and Erica S Burnell, and Neil Bannister, and Arturas Volianskis, and Georgia R Culley, and Shashank M Dravid, and Graham L Collingridge, and David E Jane, and Daniel T Monaghan
October 2013, Molecular pharmacology,
Kiran Sapkota, and Mark W Irvine, and Guangyu Fang, and Erica S Burnell, and Neil Bannister, and Arturas Volianskis, and Georgia R Culley, and Shashank M Dravid, and Graham L Collingridge, and David E Jane, and Daniel T Monaghan
January 1990, Advances in pharmacology (San Diego, Calif.),
Kiran Sapkota, and Mark W Irvine, and Guangyu Fang, and Erica S Burnell, and Neil Bannister, and Arturas Volianskis, and Georgia R Culley, and Shashank M Dravid, and Graham L Collingridge, and David E Jane, and Daniel T Monaghan
October 2005, Molecular pharmacology,
Kiran Sapkota, and Mark W Irvine, and Guangyu Fang, and Erica S Burnell, and Neil Bannister, and Arturas Volianskis, and Georgia R Culley, and Shashank M Dravid, and Graham L Collingridge, and David E Jane, and Daniel T Monaghan
January 2021, ACS chemical neuroscience,
Kiran Sapkota, and Mark W Irvine, and Guangyu Fang, and Erica S Burnell, and Neil Bannister, and Arturas Volianskis, and Georgia R Culley, and Shashank M Dravid, and Graham L Collingridge, and David E Jane, and Daniel T Monaghan
December 2011, Steroids,
Kiran Sapkota, and Mark W Irvine, and Guangyu Fang, and Erica S Burnell, and Neil Bannister, and Arturas Volianskis, and Georgia R Culley, and Shashank M Dravid, and Graham L Collingridge, and David E Jane, and Daniel T Monaghan
September 1989, Neuropharmacology,
Kiran Sapkota, and Mark W Irvine, and Guangyu Fang, and Erica S Burnell, and Neil Bannister, and Arturas Volianskis, and Georgia R Culley, and Shashank M Dravid, and Graham L Collingridge, and David E Jane, and Daniel T Monaghan
April 2024, British journal of pharmacology,
Kiran Sapkota, and Mark W Irvine, and Guangyu Fang, and Erica S Burnell, and Neil Bannister, and Arturas Volianskis, and Georgia R Culley, and Shashank M Dravid, and Graham L Collingridge, and David E Jane, and Daniel T Monaghan
August 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Kiran Sapkota, and Mark W Irvine, and Guangyu Fang, and Erica S Burnell, and Neil Bannister, and Arturas Volianskis, and Georgia R Culley, and Shashank M Dravid, and Graham L Collingridge, and David E Jane, and Daniel T Monaghan
May 2013, Molecular pharmacology,
Kiran Sapkota, and Mark W Irvine, and Guangyu Fang, and Erica S Burnell, and Neil Bannister, and Arturas Volianskis, and Georgia R Culley, and Shashank M Dravid, and Graham L Collingridge, and David E Jane, and Daniel T Monaghan
June 2016, Journal of biomolecular screening,
Copied contents to your clipboard!